研究单位：[1]Shanghai Junshi Bioscience Co., Ltd.[2]Anhui provincial hospital Hefei, Anhui, China, 230001[3]The Second Hospital of anhui Medical University Hefei, Anhui, China[4]Jiangmen central Hospital Jiangmen, Guangdong, China[5]Shenzhen people's hosptial Shenzhen, Guangdong, China, 518040[6]The fourth hospital of hebei medical university Shijiazhuang, Hebei, China, 050019河北医科大学第四医院[7]Anyang Cancer Hospital Anyang, Henan, China[8]The First Affiliated Hospital of xinxiang Medical University Xinxiang, Henan, China[9]Henan provincial pepples hospital Zhengzhou, Henan, China, 450003[10]The first affilated hospital of zhengzhou university Zhengzhou, Henan, China, 450052[11]Hunan provincial cancer hospital Changsha, Hunan, China, 410013[12]China-Japan Union hosptial of Jilin university Changchun, Jilin, China, 130031[13]The first affiliated hospital of jinzhou medical university Jinzhou, Niaoning, China, 121001[14]Shanxi provincial cancer hosptial Taiyuan, Shanxi, China, 030013[15]Affiliated Tumor Hospital of Xinjiang Medical University Ürümqi, Xinjiang, China[16]Hwa Mei Hospital,University of Chinese Academy of sciences Ningbo, Zhejiang, China, 315010[17]Taizhou hospital of zhejiang province Taizhou, Zhejiang, China, 317000[18]Beijing Cancer Hospital Beijing, China[19]Peking University Third Hospital Beijing, China[20]The General Hospital of People's Liberation Army Beijing, China[21]Heping Hospital Affiliated to changzhi Medical College Changzhi, China[22]Sichuan Cancer Hospital & Institute Chengdu, China[23]Fujian Cancer Hospital Fuzhou, China[24]3201 Hospital Hangzhou, China[25]Zhejiang Cancer Hospital Hangzhou, China[26]The First Affiliated Hospital, Zhejiang University School of Medicine Hanzhou, China[27]harbin medical university Cancer Hospital Harbin, China[28]Anhui Provincial Cancer Hospital Hefei, China[29]Huai'an First People's Hospital Huai'an, China[30]The Affiliated Hospital of jining Medical University Jining, China[31]The First Affiliated Hospital of nanchang University Nanchang, China[32]Jiangsu Cancer Hospital Nanjing, China[33]The Affiliated Hospital of Qingdao University Qingdao, China[34]Zhongshan Hospital Fudan University Shanghai, China[35]Shantou University Cancer Hospital Shantou, China[36]Liaoning cancer hospital& Institute Shenyang, China[37]Shengjing Hospital of China Medical University Shenyang, China[38]The first Hospital of china Medical University Shenyang, China[39]Tianjin Medical University Cancer Institute and Hospital Tianjin, China[40]Hubei Cancer Hospital Wuhan, China[41]Renmin Hospital of Wuhan University Wuhan, China[42]Union Hospital affiliated to Tongji Medical College of Huazhong University of Science and Technology Wuhan, China[43]The First Affiliated Hospital of Xiamen University Xiamen, China[44]Zhongshan Hospital Affiliated to Xiamen University Xiamen, China[45]Xinyang central Hospital Xinyang, China[46]The Affiliated Hospital of xuzhou Medical University Xuzhou, China[47]Yantai yuhuangding Hospital Yantai, China[48]Henan Cancer Hospital Zhengzhou, China[49]The Firest Affiliated Hospital of bengbu Medical College Bengbu, Anhui, China
研究目的：
This is a randomized, placebo-controlled, multi-center, double-blinded, Phase III study to determine the efficacy and safety of patients with locally advanced squamous cell carcinoma of the thoracic esophagus treated with perioperative immunotherapy combined with neoadjuvant chemotherapy versus placebo combined with neoadjuvant chemotherapy.
